Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) PT at $44.29

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $44.2857.

ZBIO has been the subject of a number of research analyst reports. Guggenheim raised their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Finally, Morgan Stanley raised their target price on shares of Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th.

Insider Activity at Zenas BioPharma

In other news, Director Hongbo Lu purchased 3,768 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were bought at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the completion of the transaction, the director owned 426,736 shares in the company, valued at $7,950,091.68. This represents a 0.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Fairmount Funds Management Llc purchased 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were purchased at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the transaction, the director owned 2,359,025 shares of the company’s stock, valued at $47,180,500. This trade represents a 6.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 273,768 shares of company stock worth $5,150,198. 22.00% of the stock is owned by company insiders.

Institutional Trading of Zenas BioPharma

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Zenas BioPharma by 25.0% in the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after purchasing an additional 290,307 shares during the period. Rhumbline Advisers grew its position in shares of Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the period. Bank of America Corp DE grew its position in shares of Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock valued at $136,000 after purchasing an additional 3,412 shares during the period. Sei Investments Co. acquired a new stake in shares of Zenas BioPharma in the second quarter valued at about $118,000. Finally, BNP Paribas Financial Markets grew its position in shares of Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the period.

Zenas BioPharma Trading Up 5.5%

NASDAQ:ZBIO opened at $17.84 on Friday. Zenas BioPharma has a 52 week low of $8.91 and a 52 week high of $44.60. The firm has a 50 day moving average of $20.89 and a 200 day moving average of $26.55. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -2.11 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter in the previous year, the firm posted ($0.80) EPS. As a group, sell-side analysts anticipate that Zenas BioPharma will post -4.47 earnings per share for the current fiscal year.

Key Stories Impacting Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO Leon Moulder, Jr. bought 60,000 shares for about $1.01 million, a sizable insider purchase that signals management confidence in Zenas BioPharma’s outlook. Article Title
• Positive Sentiment: Zenas BioPharma announced an upcoming presentation of Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress, which could serve as a near-term clinical catalyst if the data are well received. Article Title
• Neutral Sentiment: HC Wainwright kept a Buy rating and $44 price target on ZBIO, but lowered earnings estimates across several periods, including FY2026, FY2027, FY2028, FY2029, FY2030, and near-term quarters. The unchanged bullish rating helps, but the repeated estimate cuts point to softer expectations for profitability and can weigh on sentiment. Article Title
• Neutral Sentiment: The company also granted inducement RSUs to newly hired employees, a routine compensation move that is unlikely to be a major stock driver on its own. Article Title

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.